Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study.

Gastroenterol Rep (Oxf) · 2020 · PMC7434586 · PMID 32843978

Europe PMC DOI

hedged sentence

0.2820

closest p · 5.6× alpha

0.2820

boldest claim

The sentences

did not reach statistical significanceP = 0.282not close (p > 0.1)

Although more patients in the elderly group required IBD-related surgery while on vedolizumab, the difference did not reach statistical significance (40% vs 19%, P = 0.282).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.